Frenlosirsen (Synonyms: ION-935918; ION251) |
رقم الكتالوجGC79375
One-Click Copy Product Info
|
Frenlosirsen (ION-935918; ION251) is an antisense oligonucleotide and also an IRF4 inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2304711-81-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, Frenlosirsen (ION251) is an antisense oligonucleotide targeting IRF4. It inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells, disrupts cell cycle progression to block myeloma regeneration, and does not damage normal hematopoietic stem cells[1][2]. Frenlosirsen (28-day dosing cycle, intravenous infusion, maximum dose of 660 mg) shows no dose-limiting toxicity and only mild drug-related adverse events in a Phase 1a clinical study of relapsed/refractory multiple myeloma[2].
References:
[1]. Hartman JD, et al. Optimal conditions for quantification of IRF4 mRNA and protein as a correlative biomarker in clinical cancer studies. Journal of translational medicine. 2026 Mar 16;24(1):575.
[2]. Tong A A, et al. Abstract CT146: Safety, tolerability and molecular correlates of the IRF4-targeted antisense oligonucleotide frenlosirsen in patients with relapsed/refractory multiple myeloma: A phase 1a dose escalation trial. Cancer Research, 2025, 85(8_Supplement_2): CT146.
| Cas No. | 2304711-81-5 | SDF | |
| المرادفات | ION-935918; ION251 | ||
| Formula | C177H226N63O89P15S15 | M.Wt | 5605.63 |
| الذوبان | Storage | Store at -20°C, away from moisture | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 178.4 μL | 892 μL | 1.7839 mL |
| 5 mM | 35.7 μL | 178.4 μL | 356.8 μL |
| 10 mM | 17.8 μL | 89.2 μL | 178.4 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >96.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)